PRLD compared with GERN: revenue, margins and what each company keeps, and the suppliers and customers both name

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

GERNGeron Corp

Mkt capRevenueRevenue

Compare

PRLDPrelude Therapeutics Inc

GERNGeron Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PRLD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.9%▲+10.14%×0.56

GERN

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±18.3%▲+16.13%×0.88

Q2 FY26±13.3%▼−3.68%×0.28

= impliedPRLD realized, solidGERN realized, hatchedOne scale, both sides: full bar = 23%× = |realized| ÷ impliedSource: market data

Q1 FY26

±23.0%

▼−11.79%

×0.51

Q3 FY25±22.6%▼−5.22%×0.23

PRLDPrelude Therapeutics Inc

3.61▲+1.55%· post 3.61

Mkt cap$287.3MRevenue$6MQ2 FY26Revenue—

GERNGeron Corp

0.99▲+3.70%· post 0.99

ClosedNov 6 '26

Mkt cap$637.7MRevenue$60MQ3 FY26Revenue$184MFY25

Compare

ClosedNov 6 '26

PRLDPrelude Therapeutics Inc

GERNGeron Corp

3.61▲+1.55%post 3.61

Price

0.99▲+3.70%post 0.99

$287.3M

Mkt cap

$637.7M

Q2 FY26$6M

Revenue

$60MQ3 FY26

—

Revenue

$184MFY25

PRLD3.61▲+1.55%vsGERN0.99▲+3.70%ClosedNov 6 '26